FDA Approves Tavapadon, a New D1/D5-Targeted Parkinson Treatment
Juvmo (tavapadon), a once-daily selective D1/D5 dopamine-receptor partial agonist, has been approved for the treatment of Parkinson disease in adults.
Juvmo (tavapadon), a once-daily selective D1/D5 dopamine-receptor partial agonist, has been approved for the treatment of Parkinson disease in adults.
